GB1307271A
(en)
|
1970-06-25 |
1973-02-14 |
Shell Int Research |
Sulphoximine derivatives and their use in herbicidal compositions
|
AU770600B2
(en)
|
1999-10-07 |
2004-02-26 |
Amgen, Inc. |
Triazine kinase inhibitors
|
WO2002059110A1
(en)
|
2000-12-21 |
2002-08-01 |
Glaxo Group Limited |
Pyrimidineamines as angiogenesis modulators
|
GB0103926D0
(en)
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
WO2003037346A1
(en)
|
2001-10-31 |
2003-05-08 |
Cell Therapeutics, Inc. |
6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
|
SI2256108T1
(sl)
|
2002-07-18 |
2016-05-31 |
Janssen Pharmaceutica N.V. |
Substituirani triazinski kinazni inhibitorji
|
DE10239042A1
(de)
|
2002-08-21 |
2004-03-04 |
Schering Ag |
Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
|
AU2004212421B2
(en)
|
2003-02-07 |
2009-08-20 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl substituted pyrolls useful as inhibitors of protein kinases
|
US7151096B2
(en)
|
2003-03-05 |
2006-12-19 |
Irm Llc |
Cyclic compounds and compositions as protein kinase inhibitors
|
US8084457B2
(en)
|
2003-09-15 |
2011-12-27 |
Lead Discovery Center Gmbh |
Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
|
DE10349423A1
(de)
|
2003-10-16 |
2005-06-16 |
Schering Ag |
Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
MY169441A
(en)
|
2004-12-08 |
2019-04-11 |
Janssen Pharmaceutica Nv |
2,4, (4,6) pyrimidine derivatives
|
EP1828183A1
(en)
|
2004-12-17 |
2007-09-05 |
AstraZeneca AB |
4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors
|
EP1674470A1
(en)
|
2004-12-22 |
2006-06-28 |
Schering Aktiengesellschaft |
Sulfonamido-macrocycles as Tie2 inhibitors
|
EP1674469A1
(en)
|
2004-12-22 |
2006-06-28 |
Schering Aktiengesellschaft |
Sulfonamido-macrocycles as Tie2 inhibitors
|
WO2006106895A1
(en)
|
2005-03-30 |
2006-10-12 |
Fuji Film Corporation |
Method for casting solution
|
EP1710246A1
(en)
|
2005-04-08 |
2006-10-11 |
Schering Aktiengesellschaft |
Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
|
DE102005062742A1
(de)
|
2005-12-22 |
2007-06-28 |
Bayer Schering Pharma Ag |
Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
|
EP1803723A1
(de)
|
2006-01-03 |
2007-07-04 |
Bayer Schering Pharma Aktiengesellschaft |
(2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs
|
EP1870416A1
(en)
|
2006-06-21 |
2007-12-26 |
Bayer Schering Pharma Aktiengesellschaft |
Sulphonamido-macrocycles as tie2 inhibitors
|
EP1873159A1
(en)
|
2006-06-21 |
2008-01-02 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted sulphonamido-macrocycles as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
|
DE102006041382A1
(de)
|
2006-08-29 |
2008-03-20 |
Bayer Schering Pharma Ag |
Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
|
DE102006042143A1
(de)
|
2006-09-08 |
2008-03-27 |
Bayer Healthcare Aktiengesellschaft |
Neue substituierte Bipyridin-Derivate und ihre Verwendung
|
WO2008060248A1
(en)
|
2006-11-15 |
2008-05-22 |
S*Bio Pte Ltd. |
Indole sustituted pyrimidines and use thereof in the treatment of cancer
|
US20100093776A1
(en)
|
2006-12-22 |
2010-04-15 |
Novartis Ag |
Organic Compounds and Their Uses
|
US20100048597A1
(en)
|
2006-12-22 |
2010-02-25 |
Novartis Ag |
Organic Compounds and Their Uses
|
KR20150043565A
(ko)
|
2007-03-12 |
2015-04-22 |
와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 |
페닐 아미노 피리미딘 화합물 및 이의 용도
|
US8436007B2
(en)
|
2007-04-24 |
2013-05-07 |
Ingenium Pharmaceuticals Gmbh |
Inhibitors of protein kinases
|
WO2008129071A1
(en)
|
2007-04-24 |
2008-10-30 |
Ingenium Pharmaceuticals Gmbh |
Inhibitors of protein kinases
|
US8507498B2
(en)
|
2007-04-24 |
2013-08-13 |
Ingenium Pharmaceuticals Gmbh |
4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
|
WO2008132138A1
(en)
|
2007-04-25 |
2008-11-06 |
Ingenium Pharmaceuticals Gmbh |
Derivatives of 4,6-disubstituted aminopyrimidines
|
WO2008140420A2
(en)
|
2007-05-15 |
2008-11-20 |
S*Bio Pte Ltd |
Pyrimidine derivatives
|
EP2200436B1
(en)
|
2007-09-04 |
2015-01-21 |
The Scripps Research Institute |
Substituted pyrimidinyl-amines as protein kinase inhibitors
|
WO2009029998A1
(en)
|
2007-09-06 |
2009-03-12 |
Cytopia Research Pty Ltd |
Retrometabolic compounds
|
GB0805477D0
(en)
|
2008-03-26 |
2008-04-30 |
Univ Nottingham |
Pyrimidines triazines and their use as pharmaceutical agents
|
CA2722326A1
(en)
|
2008-04-24 |
2009-10-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
US8124764B2
(en)
|
2008-07-14 |
2012-02-28 |
Gilead Sciences, Inc. |
Fused heterocyclyc inhibitor compounds
|
US8415381B2
(en)
|
2009-07-30 |
2013-04-09 |
Novartis Ag |
Heteroaryl compounds and their uses
|
AU2010291212A1
(en)
|
2009-09-04 |
2012-02-23 |
Novartis Ag |
Heteroaryl compounds as kinase inhibitors
|
TW201111378A
(en)
|
2009-09-11 |
2011-04-01 |
Bayer Schering Pharma Ag |
Substituted (heteroarylmethyl) thiohydantoins
|
BR112012008677A2
(pt)
|
2009-10-12 |
2018-03-20 |
Myrexis Inc |
compostos amino-pirimidina como inibidores de tbkl e/ou ikk epsilon
|
HU0900798D0
(en)
|
2009-12-21 |
2010-03-01 |
Vichem Chemie Kutato Kft |
4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
|
CN102933561B
(zh)
|
2010-03-22 |
2016-05-11 |
利德发现中心有限责任公司 |
具有药学活性的二取代三嗪衍生物
|
TW201206946A
(en)
|
2010-07-15 |
2012-02-16 |
Bristol Myers Squibb Co |
Compounds for the reduction of beta-amyloid production
|
WO2012066065A1
(en)
|
2010-11-17 |
2012-05-24 |
Novartis Ag |
Phenyl-heteroaryl amine compounds and their uses
|
EA201390717A1
(ru)
|
2010-11-17 |
2013-10-30 |
Новартис Аг |
3-(аминоарил)пиридиновые соединения
|
WO2012101066A1
(en)
|
2011-01-28 |
2012-08-02 |
Novartis Ag |
Pyridine biaryl amine compounds and their uses
|
WO2012101064A1
(en)
|
2011-01-28 |
2012-08-02 |
Novartis Ag |
N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
|
WO2012101065A2
(en)
|
2011-01-28 |
2012-08-02 |
Novartis Ag |
Pyrimidine biaryl amine compounds and their uses
|
CN103339110A
(zh)
|
2011-01-28 |
2013-10-02 |
诺瓦提斯公司 |
作为cdk9抑制剂的取代的杂-联芳基化合物及其用途
|
WO2012101063A1
(en)
|
2011-01-28 |
2012-08-02 |
Novartis Ag |
N-acyl pyridine biaryl compounds and their uses
|
US9242937B2
(en)
|
2011-03-02 |
2016-01-26 |
Bayer Intellectual Property Gmbh |
Pharmaceutically active disubstituted pyridine derivatives
|
WO2012117048A1
(en)
|
2011-03-02 |
2012-09-07 |
Lead Discovery Center Gmbh |
Pharmaceutically active disubstituted triazine derivatives
|
CA2832919A1
(en)
|
2011-04-12 |
2012-10-18 |
Ryan C. Holcomb |
Compounds, compositions, and therapeutic uses thereof
|
CN102731413A
(zh)
|
2011-04-15 |
2012-10-17 |
上海医药工业研究院 |
一种脲类化合物、其制备方法、其中间体及其应用
|
MX2013012233A
(es)
|
2011-04-19 |
2014-01-23 |
Bayer Pharma AG |
4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas.
|
EP2527332A1
(en)
|
2011-05-24 |
2012-11-28 |
Bayer Intellectual Property GmbH |
4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
|
CA2848616A1
(en)
|
2011-09-16 |
2013-03-21 |
Bayer Intellectual Property Gmbh |
Disubstituted 5-fluoro-pyrimidines
|
EP2755948B1
(en)
|
2011-09-16 |
2016-05-25 |
Bayer Intellectual Property GmbH |
Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
|
ES2661717T3
(es)
|
2012-08-23 |
2018-04-03 |
Virostatics Srl |
Derivados de aminopirimidina 4,6-disustituidos novedosos
|
CA2888381A1
(en)
|
2012-10-18 |
2014-04-24 |
Bayer Pharma Aktiengesellschaft |
4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group
|
CN104854091B
(zh)
|
2012-10-18 |
2018-04-03 |
拜耳药业股份公司 |
含砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物
|
ES2616441T3
(es)
|
2012-10-18 |
2017-06-13 |
Bayer Pharma Aktiengesellschaft |
Derivados de N-(piridin-2-il))pirimidin-4-amina que contienen un grupo sulfona
|
TW201418243A
(zh)
|
2012-11-15 |
2014-05-16 |
Bayer Pharma AG |
含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
|
AP3872A
(en)
|
2012-11-15 |
2016-10-31 |
Bayer Pharma AG |
5-Fluoro-n-(pyridin-2-yl) pyridin-2-amine derivatives containing a sulfoximine group
|
EP2920153B1
(en)
|
2012-11-15 |
2017-02-01 |
Bayer Pharma Aktiengesellschaft |
4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group
|
US20150368209A1
(en)
|
2013-01-07 |
2015-12-24 |
École Polytechnique Fédérale De Lausanne (Epfl) |
4-Pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (PLK1) for the treatment of cancer and their use for the treatment of bacterial infections
|
US9770445B2
(en)
|
2013-07-04 |
2017-09-26 |
Bayer Pharma Aktiengesellschaft |
Sulfoximine substituted 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives and their use as CDK9 kinase inhibitors
|
US9856242B2
(en)
|
2014-03-13 |
2018-01-02 |
Bayer Pharma Aktiengesellscaft |
5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
|
CA2944251C
(en)
|
2014-04-01 |
2022-10-18 |
Bayer Pharma Aktiengesellschaft |
Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
|
MA39822A
(fr)
|
2014-04-03 |
2018-02-06 |
Janssen Pharmaceutica Nv |
Dérivés de pyrimidine bicycle
|
MA39823A
(fr)
|
2014-04-03 |
2018-01-09 |
Janssen Pharmaceutica Nv |
Dérivés de pyridine macrocyclique
|
TN2016000435A1
(en)
|
2014-04-11 |
2018-04-04 |
Bayer Pharma AG |
Novel macrocyclic compounds.
|
CN108290903B
(zh)
|
2015-09-29 |
2021-09-03 |
拜耳医药股份有限公司 |
新的大环磺酰二亚胺化合物
|
EP3359544B1
(en)
*
|
2015-10-08 |
2020-08-12 |
Bayer Pharma Aktiengesellschaft |
Novel modified macrocyclic compounds
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
WO2018177889A1
(en)
|
2017-03-28 |
2018-10-04 |
Bayer Aktiengesellschaft |
Novel ptefb inhibiting macrocyclic compounds
|
EP3601253B1
(en)
|
2017-03-28 |
2021-09-15 |
Bayer Aktiengesellschaft |
Novel ptefb inhibiting macrocyclic compounds
|